Diabetic Kidney Disease: Combo Therapy Targets Zombie Cells

Key Points

• Researchers from Mayo Clinic identified a combination therapy that may reduce harmful senescent cells in diabetic kidney disease.
• The therapy combines Dasatinib and Quercetin, a natural plant compound.
• Preclinical findings show reduced inflammation, improved kidney function, and increased protective factors.
• The study was published in eBioMedicine, suggesting senolytic therapies may support kidney health in diabetes.

Diabetic Kidney Disease: Combination Therapy Targets Senescent Cells

Diabetic kidney disease remains the leading cause of kidney failure, affecting more than 12 million individuals in the United States alone. While several therapies can slow kidney damage, clinicians still face a major challenge: there is no definitive cure.

A research team from Mayo Clinic has reported promising results from a combination therapy designed to eliminate senescent cells, often referred to as “zombie cells.” These cells accumulate in tissues and contribute to inflammation, aging processes, and organ damage.

Published in eBioMedicine, the study indicates that combining Dasatinib, a cancer drug, with Quercetin, a naturally occurring flavonoid, may reduce cellular senescence and improve kidney health in diabetic conditions.

How Senolytic Therapy Targets Senescent Cells in Diabetic Kidney Disease

In diabetic kidney disease, long-term metabolic stress contributes to tissue injury and the accumulation of senescent cells. Unlike normal cells, these cells fail to undergo programmed cell death and instead remain active in tissues, releasing inflammatory signals that worsen organ damage.

Researchers have increasingly explored senolytics, a class of therapies designed to selectively remove these dysfunctional cells.

The team, led by LaTonya Hickson, evaluated the impact of the Dasatinib–Quercetin combination in a preclinical model of diabetic kidney disease. The therapy was administered over a short treatment course.

Results showed:

• A reduction in senescent cell burden
• Lower inflammatory markers in kidney tissue
• Improved kidney function and protective factors

Laboratory experiments using cultured human kidney cells also confirmed that the therapy decreased senescent cells and the inflammatory pathways they trigger.

Explore All Nephrology CME Conferences and Online Courses

Clinical Implications for Kidney Function and Future Studies

Interest in targeting senescence has been growing as researchers seek new ways to slow organ deterioration in chronic diseases. In an earlier pilot clinical trial, investigators from Mayo Clinic reported that the same combination therapy reduced senescent cells in the skin and fat tissue of patients with diabetic kidney disease.

However, its direct impact on kidney tissue had not been previously demonstrated.

Lead author Xiaohui Bian emphasized that the study aimed to confirm kidney effects using noninvasive approaches rather than invasive procedures.

The findings showed that the therapy not only reduced senescence but also improved markers associated with kidney protection and tissue repair.

For nephrologists and clinicians managing diabetic complications, the results suggest that senolytic therapies may provide a new strategy to slow kidney damage. Researchers note that larger clinical studies will be required to confirm safety, dosing, and long-term benefits.

If validated in future trials, this approach could help reduce inflammation, limit tissue injury, and potentially slow the progression of diabetic kidney disease.

Source:

Mayo Clinic